All In Biotech

Drug Trial Radar · NCT04720378

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection

Last checked: Nov 19, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

May 30, 2021

Primary completion

May 3, 2022

Study completion May 3, 2022

Sponsor

Sponsor type
Industry
Collaborators
IQVIA Biotech
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.

Conditions

  • Cytokine Release Syndrome

Interventions

  • ST266Biological

    1X ST266

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-Emergent Adverse EventsTime frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Innovative Research of West Florida

    Clearwater, Florida

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • WR-ClinSearch, LLC

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.